carfilzomib + melphalan + prednisone

This is a **combination regimen** consisting of three agents: - **Carfilzomib** is a selective, irreversible proteasome inhibitor (20S core particle of the 26S proteasome), leading to accumulation of polyubiquitinated proteins and apoptosis in malignant plasma cells. - **Melphalan** is an alkylating agent that induces DNA cross-linking, preventing DNA replication and RNA transcription, resulting in cell death, particularly in rapidly dividing cells. - **Prednisone** is a synthetic glucocorticoid corticosteroid that induces apoptosis in lymphoid cells and modulates inflammation and immune response. This specific combination is used for **multiple myeloma**, particularly for elderly or transplant-ineligible patients, and was studied in randomized clinical trials such as CLARION to compare efficacy and safety with the established bortezomib-containing regimens[3][4][5][6]. Carfilzomib is developed by Amgen and is marketed as Kyprolis[1][2][5][6]. Melphalan is manufactured under brand names such as Alkeran, originally by GSK, now produced by Aspen. Prednisone is produced as a generic product by numerous manufacturers. As of 2019, Kyprolis (carfilzomib) in combination with melphalan and prednisone was not approved by FDA for newly diagnosed transplant-ineligible multiple myeloma patients[6].

Brand names

Kyprolis + Alkeran + generic prednisone

Other names

KMPcarfilzomib-melphalan-prednisone